Primary Surgical Prevention of Breast Cancer-related Lymphedema (LYMPHA)
Effect of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) for Primary Surgical Prevention of Breast Cancer-related Lymphedema
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Soong June Bae, M.D.
- Phone Number: 82-2-2019-4401
- Email: mission815815@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of, 06273
- Recruiting
- Gangnam Severance Hospital, Yonsei University College of Medicine
-
Contact:
- Soong June Bae, M.D.
- Phone Number: 82-2-2019-4401
- Email: mission815815@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age over 19 years old
- Patients who are expected to undergo surgery under the diagnosis of breast cancer, and are determined to undergo axillary lymph node dissection before surgery.
Exclusion Criteria:
- Patients with vascular and lymph-related diseases
- Patients with a history of surgical treatment or trauma to both arms and axillary
- Patients with a history of receiving radiation treatment in both arms, chest, and axilla
- Patients with confirmed systemic metastasis with stage 4 breast cancer
- Pregnant and lactating patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LYMPHA
LYMPHA procedure is performed in which the lymphatic vessels drained from the arm and the axillary vein are micro-bonded to the side branches.
|
Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated.
Subsequently, the occurrence of lymphedema is followed up.
|
|
Active Comparator: Control
No LYMPHA procedure is performed
|
In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures.
Subsequently, the occurrence of lymphedema is followed up.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of lymphedema
Time Frame: 2 years after surgery
|
To compare the incidence of lymphedema assessed by UEL index and lymphoscintigraphy at 2 years after the surgery.
|
2 years after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
UEL index
Time Frame: 2 years after surgery
|
To compare the UEL index
|
2 years after surgery
|
|
Changes in Lymphoscintigraphy
Time Frame: 2 years after surgery
|
To compare the changes in lymphoscintigraphy presented by the change of transport index (TI)
|
2 years after surgery
|
|
Incidence of lymphedema
Time Frame: 5 years after surgery
|
To compare the incidence of lymphedema assessed by UEL index and lymphoscintigraphy at 5 years after the surgery.
|
5 years after surgery
|
|
5-year recurrence rate
Time Frame: 5 years after surgery
|
To compare the recurrence rate
|
5 years after surgery
|
|
5-year overall survival rate
Time Frame: 5 years after surgery
|
To compare the overall survival rate
|
5 years after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 3-2020-0343
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.